This is the old version of SRDR. The next, SRDRplus is available! Registration of your SRDRPlus account is free and approval is automatic. Click Here to register an SRDRPlus account.

Advanced Search

Study Preview



Study Title and Description

Plasma eicosapentaenoic acid is negatively associated with all-cause mortality among men and women in a population-based prospective study.



Key Questions Addressed
2 Observational studies (longitudinal; quantile or continuous analysis)
  • Comments Comments (
    0
    ) |

Primary Publication Information
  • Comments Comments (
    0
    ) |
TitleData
Title Plasma eicosapentaenoic acid is negatively associated with all-cause mortality among men and women in a population-based prospective study.
Author Miura K., Hughes MCB., Ungerer JP., Green AC.
Country QIMR Berghofer Medical Research Institute, Cancer and Population Studies Group, 300 Herston Rd, Herston, Brisbane, Queensland 4006, Australia. Electronic address: Kyoko.Miura@qimrberghofer.edu.au.
Year 2016
Numbers Pubmed ID: 27865614

Secondary Publication Information
There are currently no secondary publications defined for this study.


Extraction Form: Observational Studies
Design Details
Question... Follow Up Answer Follow-up Answer
Study Design Observational: Prospective, longitudinal study of intake (eg, FFQ, biomarker)
  • Comments Comments (
    0
    ) |
What is the name of this study? (e.g. DART, Physician's Health Study)
  • Comments Comments (
    0
    ) |
Country in which study conducted (where subjects live) ... Specify Other(s) [Separate countries with commas]: ... Australia
  • Comments Comments (
    0
    ) |
Funding source No industry relationship reported (funding or affiliations reported)
  • Comments Comments (
    0
    ) |
Eligibility Criteria: Nambour residents aged 20 to 69 years, who provided blood samples during a follow-up clinic in August 1996 and were alive on January 1, 1997
  • Comments Comments (
    0
    ) |
Comment about Eligibility Criteria:
  • Comments Comments (
    0
    ) |
Study Population Primary Prevention, Healthy
  • Comments Comments (
    0
    ) |
Comment about study design:
  • Comments Comments (
    0
    ) |
Conflict of interest No conflict of interest (explicitly stated)
  • Comments Comments (
    0
    ) |
Does the study report a subgroup or predictor (regression) analysis for an outcome of interest? ... Which subgroups/predictors? Yes ... gender
  • Comments Comments (
    0
    ) |
What type(s) of analysis is/are reported? Baseline biomarker level vs. outcomes
  • Comments Comments (
    0
    ) |
Study start date(s) 1996
  • Comments Comments (
    0
    ) |
Male, percent 44
  • Comments Comments (
    0
    ) |
Race
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Dropouts, withdrawals, etc.
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Comments about quantiles.
  • Comments Comments (
    0
    ) |
Baseline characteristics, continuous 50
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
12
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
26.6
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
4.2
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
Baseline Diseases/Conditions
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
  • Comments Comments (
    0
    ) |
n3 Source Diet (Total)
  • Comments Comments (
    0
    ) |




Results & Comparisons

No Results found.

Quality Dimensions
Dimension Value Notes Comments
Selection bias (NOT NESTED CASE CONTROL): Is there clear demonstration that the outcome of interest was not present at the start of the study (baseline)? Yes
  • Comments Comments (
    0
    ) |
Comparability/Adjustment (ALL OBSERVATIONAL STUDIES): Were the analyses adjusted for confounders (or other factors)? Yes
  • Comments Comments (
    0
    ) |
Outcome assessment (ALL STUDIES): Were OUTCOME ASSESSORS adequately BLINDED? Yes
  • Comments Comments (
    0
    ) |
Incomplete outcome data (attrition bias) due to amount, nature or handling of incomplete outcome data (ALL STUDIES) No
  • Comments Comments (
    0
    ) |
Nutrition, FFQ Baseline intake: Was the dietary assessment instrument (eg, FFQ) described to have measured n-3 FA (ALL STUDIES WITH FFQ)? Yes
  • Comments Comments (
    0
    ) |
Nutrition, Baseline data: Were the ranges or distributions of the nutrient exposures adequately reported (ie, quantile means/medians SD and/or ranges) (ALL OBSERVATIONAL STUDIES)? Yes
  • Comments Comments (
    0
    ) |
Additional Bias: Bias due to problems not covered elsewhere in the table. No
  • Comments Comments (
    0
    ) |
Do any specific outcomes have a high risk of bias (different than others)? If so, describe in Notes. No
  • Comments Comments (
    0
    ) |

Quality Rating
No quality rating data was found.